Spots Global Cancer Trial Database for Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
Official Title: The Phase II of Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
Study ID: NCT02591784
Conditions
Study Description
Brief Summary: Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The phase II study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with radiotherapy in patients with esophageal cancer tumours.
Detailed Description: Clinical efficacy has been shown in adult with head and neck cancer. The phase II study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with radiotherapy in patients with esophageal cancer tumours.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Affiliated tumour hosiptal of HARBIN Medical University, Harbin, Heilongjiang, China
Wuhan Union Hospital, Wuhan, Hubei, China
Qilu Hospital,Shandong University, Jinan, Shandong, China
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, , China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, , China
Contact Details
Name: Lvhua Wang
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
